{"product_id":"getinge-bcg-matrix","title":"Getinge Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eActionable Strategy Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eGetinge's BCG Matrix preview highlights its portfolio balance across high-growth innovators and steady earners — pinpointing where market leadership, investment, or divestment may be needed; this snapshot teases strategic patterns but stops short of granular action. Purchase the full BCG Matrix for quadrant-level placements, data-backed recommendations, and ready-to-use Word and Excel deliverables that translate insights into clear investment and product decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eECMO and Extracorporeal Life Support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGetinge holds a leading global share in ECMO (extracorporeal membrane oxygenation) with Rotaflow and Cardiohelp; ECMO market size was about USD 1.6B in 2024 and is forecasted to grow ~8% CAGR to 2029, boosting Getinge’s high-margin device sales.\u003c\/p\u003e\n\u003cp\u003eClinical use of ECMO has expanded from cardiac surgery to long-term respiratory failure and ARDS, increasing consumable use; disposables delivered recurring revenue of ~€300–€400M across the business in 2024.\u003c\/p\u003e\n\u003cp\u003eThis segment demands heavy R and D—Getinge spent ~3–4% of revenues on R and D in 2024—to keep technological lead versus Abiomed and LivaNova, but it remains a major profit driver due to premium hardware pricing and recurring sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBioprocessing Systems for Life Science\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGetinge’s Bioprocessing Systems, strengthened by the 2021 Applikon acquisition, sits in the Stars quadrant with ~20–25% CAGR demand for bioreactors as vaccine and biologics production rises; global single‑use and stainless reactor markets hit ~$5.5B in 2024. \u003c\/p\u003e\n\u003cp\u003eThe unit benefits from personalized medicine and large‑scale cell culture trends, commanding a high share in critical biomanufacturing infrastructure while consuming cash for capacity expansion and R\u0026amp;D to support projected double‑digit revenue growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Health and Workflow Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSoftware like T-DOC (sterile supply) and INSIGHT (patient flow) sit in Getinge’s Stars: digital health and workflow solutions, a high-growth area as hospital IT spend rose 9.2% in 2024 to $71.5B globally (HIMSS 2024), driving demand for OR and CSSD (central sterile services) automation.\u003c\/p\u003e\n\u003cp\u003eGetinge’s edge: integrating these platforms with installed hardware boosts recurring software revenue—2024 service\/software sales grew ~12% YoY, shifting mix from capital goods to services and subscriptions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEndovascular Grafts and Stents\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe cardiovascular segment shows ~6–8% annual growth for endovascular procedures; Getinge holds a notable share via Advanta V12 covered stents and vascular disposables, with 2024 unit sales up ~12% y\/y and estimated revenues ~€70–90M for the portfolio.\u003c\/p\u003e\n\u003cp\u003eOngoing clinical trials (3 active trials through 2025) and expansion into India\/Brazil\/MENA drive volume; competitors include Medtronic and Boston Scientific, so Getinge must sustain marketing, KOL engagement, and postmarket data to defend share.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAdvanta V12: ~12% sales growth 2024\u003c\/li\u003e\n\u003cli\u003ePortfolio revenue est €70–90M\u003c\/li\u003e\n\u003cli\u003e3 active clinical trials to 2025\u003c\/li\u003e\n\u003cli\u003eEmerging markets: India, Brazil, MENA\u003c\/li\u003e\n\u003cli\u003eHigh marketing \u0026amp; clinical support needed\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Robotic Operating Room Integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGetinge’s hybrid ORs are now core as robotic surgery rises: the global surgical robotics market hit $6.8B in 2024 and is projected CAGR 16% to 2030, so integrated imaging, modular rooms, and specialized tables make Getinge a market leader in high-end surgical environments.\u003c\/p\u003e\n\u003cp\u003eDemand is driven by hospital modernization and stand-alone surgical centers; projects require heavy engineering and PM—Getinge’s 2024 capital projects and R\u0026amp;D spend (~SEK 4.1B) underpin this leadership in a complex tech landscape.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket size 2024: $6.8B (surgical robotics)\u003c\/li\u003e\n\u003cli\u003eProjected CAGR: ~16% (2024–2030)\u003c\/li\u003e\n\u003cli\u003eGetinge R\u0026amp;D\/capex 2024: ~SEK 4.1B\u003c\/li\u003e\n\u003cli\u003eRevenue mix: high-margin installation \u0026amp; service in hybrid ORs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGetinge's Growth Engines: ECMO, Bioprocessing, Software \u0026amp; Hybrid ORs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGetinge’s Stars: ECMO (~$1.6B 2024; ~8% CAGR to 2029), Bioprocessing (~$5.5B 2024; 20–25% CAGR), Software\/services (hospital IT spend $71.5B 2024; service\/software +12% YoY), Hybrid ORs (surgical robotics $6.8B 2024; 16% CAGR).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003e2024 size\u003c\/th\u003e\n\u003cth\u003eCAGR\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eECMO\u003c\/td\u003e\n\u003ctd\u003e$1.6B\u003c\/td\u003e\n\u003ctd\u003e~8%\u003c\/td\u003e\n\u003ctd\u003eHigh-margin devices\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBioprocessing\u003c\/td\u003e\n\u003ctd\u003e$5.5B\u003c\/td\u003e\n\u003ctd\u003e20–25%\u003c\/td\u003e\n\u003ctd\u003eCapacity spend\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSoftware\u003c\/td\u003e\n\u003ctd\u003e$71.5B (IT)\u003c\/td\u003e\n\u003ctd\u003en\/a\u003c\/td\u003e\n\u003ctd\u003e+12% services\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHybrid ORs\u003c\/td\u003e\n\u003ctd\u003e$6.8B\u003c\/td\u003e\n\u003ctd\u003e16%\u003c\/td\u003e\n\u003ctd\u003eHigh-install margins\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eComprehensive BCG Matrix for Getinge: quadrant-level analysis, strategic moves to invest, hold, or divest, and competitive risks and opportunities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page overview placing Getinge business units into BCG quadrants for quick strategic clarity and executive decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSterile Reprocessing Equipment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGetinge leads the mature market for autoclaves, washer-disinfectors, and steam sterilizers, with an estimated global installed base exceeding 200,000 units as of 2025, driving predictable replacement sales and service revenue that contributed roughly SEK 6.5bn in service income in FY2024.\u003c\/p\u003e \n\u003cp\u003eStable tech means lower marketing spend versus growth segments, yielding strong cash conversion—sterile reprocessing EBITDA margins around 18–22%—so these cash flows finance Getinge’s push into digital health and life-science offerings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSurgical Tables and Patient Positioning\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGetinge’s Maquet surgical tables compete in a mature global market valued at about $2.4bn in 2024, where Maquet holds a substantial, stable share—roughly 12–15%—driving predictable replacement cycles and steady installed-base sales.\u003c\/p\u003e\n\u003cp\u003eHigh gross margins (~38% in 2024 for Getinge’s OR equipment segment) come from scale manufacturing and premium positioning, making surgical tables a cash cow that reliably funds debt service and dividends, contributing materially to free cash flow (Getinge FCF margin ~8% in 2024).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTraditional Mechanical Ventilators\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDespite post‑pandemic normalization, the Servo ventilator brand dominates ICU share; Getinge reported respiratory device sales of SEK 6.2bn in 2024, with servo models a core contributor.\u003c\/p\u003e\n\u003cp\u003eThe high‑quality ventilator market is mature; Getinge’s reputation drives steady replacement\/upgrades—global ICU unit growth ≈1–2% annually—supporting predictable product demand.\u003c\/p\u003e\n\u003cp\u003eService contracts and consumables (breathing circuits) generated ~15% of Getinge’s 2024 revenue, yielding recurring cash with little incremental capex.\u003c\/p\u003e\n\u003cp\u003eThis cash cow preserves ICU presence and frees growth capital for higher‑return segments like advanced extracorporeal systems.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOperating Room Lights and Visualization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSurgical lighting systems are a cash cow for Getinge: high market share, low growth, with global OR lighting market steady at ~3% CAGR and LED adoption \u0026gt;75% in 2024.\u003c\/p\u003e\n\u003cp\u003eGetinge’s LED tech and modular light arms are industry standards, requiring minimal promotion; replacement cycles of 8–12 years drive stable revenue—product margins near 28% in 2024.\u003c\/p\u003e\n\u003cp\u003ePrimary focus: operational excellence and cost reduction—automation in manufacturing cut COGS ~4% in 2024—so cash flow funds R\u0026amp;D and surgical workplace investments.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh share, low growth (3% CAGR)\u003c\/li\u003e\n\u003cli\u003eLED adoption \u0026gt;75% (2024)\u003c\/li\u003e\n\u003cli\u003eReplacement cycle 8–12 yrs\u003c\/li\u003e\n\u003cli\u003eMargins ~28% (2024)\u003c\/li\u003e\n\u003cli\u003eCOGS cut ~4% (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAnesthesia Delivery Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe Flow-i and Flow-c anesthesia machines are well-established globally, driving stable surgical-segment revenue and contributing to Getinge’s high-margin cash flow; in 2024 anesthesia systems accounted for about 18% of Getinge’s Surgical Workflows revenue, supporting predictable operating cash. Long product lifecycles and strict regulatory barriers keep competitors out, and Getinge’s procurement relationships sustain a leading market share estimated near 25%–30% in key regions. This predictable business is a core cash cow for long-term financial health.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFlow-i\/Flow-c: core products, ~18% of Surgical Workflows revenue (2024)\u003c\/li\u003e\n\u003cli\u003eMarket share: ~25%–30% in major markets\u003c\/li\u003e\n\u003cli\u003eHigh barriers: long lifecycles, strict regulation\u003c\/li\u003e\n\u003cli\u003eFinancial role: stable, high-margin cash generation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGetinge’s cash cows: predictable high-margin service revenues funding R\u0026amp;D \u0026amp; M\u0026amp;A\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGetinge’s cash cows—sterile reprocessing, Maquet surgical tables, Servo ventilators, OR lighting, and Flow anesthesia—delivered predictable replacement\/service revenue with FY2024 service income ~SEK 6.5bn, segment margins 18–38%, and group FCF margin ~8%, funding R\u0026amp;D and M\u0026amp;A.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2024 metric\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSterile reprocessing\u003c\/td\u003e\n\u003ctd\u003eInstalled base \u0026gt;200,000; service SEK 6.5bn\u003c\/td\u003e\n\u003ctd\u003eStable recurring cash\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMaquet tables\u003c\/td\u003e\n\u003ctd\u003eMarket ~$2.4bn; share 12–15%\u003c\/td\u003e\n\u003ctd\u003eHigh margin cash\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eServo ventilators\u003c\/td\u003e\n\u003ctd\u003eRespiratory sales SEK 6.2bn; consumables 15% rev\u003c\/td\u003e\n\u003ctd\u003eRecurring cash\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOR lighting\u003c\/td\u003e\n\u003ctd\u003eMargins ~28%; LED adoption \u0026gt;75%\u003c\/td\u003e\n\u003ctd\u003eLow promo, steady\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFlow anesthesia\u003c\/td\u003e\n\u003ctd\u003e~18% Surgical rev; share 25–30%\u003c\/td\u003e\n\u003ctd\u003ePredictable cash\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You’re Viewing Is Included\u003c\/span\u003e\u003cbr\u003eGetinge BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you’re previewing on this page is the exact Getinge BCG Matrix report you’ll receive after purchase—no watermarks, no demo placeholders, just the fully formatted, analysis-ready document crafted for strategic clarity and professional use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56748048843129,"sku":"getinge-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/getinge-bcg-matrix.png?v=1772204209","url":"https:\/\/growthsharematrix.com\/products\/getinge-bcg-matrix","provider":"Growth Share Matrix","version":"1.0","type":"link"}